Delcath Systems, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe. Its primary product, CHEMOSAT/Melphalan/HDS, is intended to deliver regional chemotherapy for liver cancers. CHEMOSAT is CE-marked and commercially available in Europe, while Melphalan/HDS is not approved for sale in the United States. The filing covers the three months ended March 31, 2015, compared with the three months ended March 31, 2014.
The company is pursuing a planned global Phase 3 ocular melanoma trial and Phase 2 programs in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. During the first quarter, 26 commercial CHEMOSAT treatments were performed in Europe, bringing cumulative treatments since the February 2012 launch to 182.
Financial Condition and Results
| Metric | Q1 2015 | Q1 2014 | Change |
|---|---|---|---|
| Revenue | $0.444 million | $0.310 million | 43.2% increase |
| Cost of goods sold | $0.133 million | $0.093 million | 43.0% increase |
| Gross profit | $0.311 million | $0.217 million | 43.3% increase |
| Gross margin | 70.0% | 70.0% | Stable |
| Operating expenses | $4.019 million | $5.276 million | 23.8% decrease |
| Operating loss | $(3.708) million | $(5.059) million | 26.7% improvement |
| Net loss | $(3.488) million | $(5.278) million | 33.9% improvement |
| Loss per share | $(0.32) | $(0.57) | Improved |
| Cash used in operating activities | $(4.414) million | $(4.487) million | Improved by $0.073 million |
| Cash and cash equivalents | $18.462 million | $31.254 million at March 31, 2014 | Year-over-year decrease |
Gross margin was approximately 70%. Net loss margin was approximately negative 786% of revenue, compared with approximately negative 1,703% in the prior-year quarter. The company remains unprofitable and has accumulated a deficit of $250.0 million at March 31, 2015.
Total assets were $21.650 million and total liabilities were $5.226 million at March 31, 2015. Current assets were $20.030 million, including $18.462 million of cash and cash equivalents. Current liabilities were $4.239 million, including an $0.836 million warrant liability. The filing discusses a revolving line facility fee, but does not provide a clear outstanding debt balance.
Material Changes Versus the Prior Comparable Period
- Revenue increased by $0.134 million, reflecting early European commercial activity.
- Selling, general and administrative expense decreased to $3.040 million from $3.819 million. The 2015 amount included approximately $0.403 million of workforce restructuring charges; excluding that charge, the decrease was approximately $1.2 million.
- Research and development expense decreased to $0.979 million from $1.457 million, primarily due to the phasing out of the medical science liaison program and workforce-related cost reductions.
- Net loss improved by $1.790 million, aided by lower operating expenses, higher gross profit, and a favorable $0.209 million change in the fair value of the warrant liability. The warrant adjustment was non-cash.
- In February 2015, the company sold 2.5 million common shares and issued warrants for approximately 1.1 million shares, generating net proceeds of approximately $2.5 million. The financing increased common shares outstanding and diluted potential ownership.
- The warrant liability increased from $0.225 million at December 31, 2014 to $0.836 million at March 31, 2015, principally because of the February 2015 warrant issuance.
- The company recorded $0.045 million of capital expenditures in the quarter, compared with none in the prior-year quarter.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management believes existing capital resources are adequate to fund operations into the first half of 2016, but states that additional working capital will be required to continue clinical development and fully commercialize the product.
- Because the business does not generate positive operating cash flow, the company expects to seek additional financing through borrowing, equity sales, or strategic alliances. However, the company stated that it had reached the applicable Form S-3 public-float limitation and was then unable to access its ATM program or otherwise use the Form S-3 unless its market value increased.
- The FDA issued a Complete Response Letter in September 2013. The company plans a new randomized Phase 3 ocular melanoma trial using overall survival as the primary endpoint to support a potential U.S. resubmission. U.S. approval remains uncertain.
- Protocol 201 in the United States opened for HCC enrollment in October 2014, with Montefiore Medical Center opening in April 2015. Three German hospitals had opened enrollment under the European HCC protocol, and the company expected to add an ICC cohort in 2015.
- European commercialization depends heavily on reimbursement. Germany granted another year of NUB Value 4 coverage, which permits negotiated reimbursement but does not mandate payment. U.K. reimbursement and funding initiatives remained uncertain and subject to delays.
- The company reports significant historical procedure risks, including severe bone marrow suppression, febrile neutropenia, stroke, myocardial infarction, hepatic injury, severe hemorrhage, gastrointestinal perforation, and treatment-related deaths. The company believes subsequent product and procedure refinements improved safety, but clinical validation remains ongoing.
- Restructuring reserves at March 31, 2015 included approximately $0.869 million for employee costs and $1.195 million for lease liabilities. The company had reduced its workforce by 59 employees since 2013.
- Several securities and derivative-related shareholder lawsuits remained pending. The securities class action had reached a settlement in principle subject to court approval; related derivative matters were stayed or being explored for settlement, while defendants denied wrongdoing.
- The company disclosed no material changes to the risk factors in its 2014 Form 10-K and reported that disclosure controls and procedures were effective as of March 31, 2015.
Most Important Facts for an Investor to Verify
- Whether cash resources and subsequent financing were sufficient to sustain operations beyond the first half of 2016.
- Whether the company regained access to its ATM or Form S-3 financing capacity and on what terms, including potential dilution.
- Progress, enrollment, safety data, and regulatory requirements for the planned Phase 3 ocular melanoma trial and Phase 2 HCC/ICC programs.
- Whether CHEMOSAT reimbursement improved in Germany, the United Kingdom, and other European markets, and whether treatment volumes translated into material revenue growth.
- The status and ultimate cost of the securities and derivative litigation settlements.
- The outstanding warrant count, exercise prices, potential dilution, and future volatility of the warrant liability.
- The actual outstanding balance and terms of any revolving or other debt facility, which the filing text does not state clearly.